Evidence map›Paper›PMID 36383140›Full record

ArticleAIDS patient care and STDs2022

Back2PrEP: Rates of Bacterial Sexually Transmitted Infection Diagnosis Among Individuals Returning to HIV Pre-Exposure Prophylaxis Care: A Retrospective Review of a New York City Comprehensive HIV Prevention Program.

Jacob McLean, Logan Bartram, Jason Zucker, Elijah LaSota, Caroline Carnevale, Paul Richards, Edward Perez, Kanako Mori, Ofole Mgbako, Susan Olender and 3 more

Open access · greenAbstract read
In one paragraph

Article in AIDS patient care and STDs, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed, 5 citations in OpenAlex.

  1. Trial
  2. Article
  3. Article
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 4 institutions in 1 country.

Jacob McLeanDivision of Infectious Diseases, Department of Internal Medicine, Columbia University Irving Medical Center, New York City, New York, USA.ORCID 0000-0002-4961-3487
Logan BartramDivision of Infectious Diseases, Department of Internal Medicine, Icahn School of Medicine at Mount Sinai, New York City, New York, USA.
Jason ZuckerDivisions of Infectious Diseases, Department of Internal Medicine and Pediatrics, Columbia University Irving Medical Center, New York City, New York, USA.ORCID 0000-0001-6987-6412
Elijah LaSotaDivision of Infectious Diseases, Department of Internal Medicine, Columbia University Irving Medical Center, New York City, New York, USA.
Caroline CarnevaleHIV Prevention Program, New York Presbyterian/Columbia University Irving Medical Center Hospital Comprehensive Health Program, New York City, New York, USA.
Paul RichardsHIV Prevention Program, New York Presbyterian/Columbia University Irving Medical Center Hospital Comprehensive Health Program, New York City, New York, USA.
Edward PerezHIV Prevention Program, New York Presbyterian/Columbia University Irving Medical Center Hospital Comprehensive Health Program, New York City, New York, USA.
Kanako MoriDivision of Infectious Diseases, Department of Internal Medicine, Columbia University Irving Medical Center, New York City, New York, USA.
Ofole MgbakoDivision of Infectious Diseases and Immunology, Department of Medicine, NYU Langone Health, New York City, New York, USA.ORCID 0000-0002-8955-4303
Susan OlenderDivision of Infectious Diseases, Department of Internal Medicine, Columbia University Irving Medical Center, New York City, New York, USA.
Alwyn CohallSociomedical Sciences, Population and Family Health, and Pediatrics, Mailman School of Public Health and Columbia University Medical Center, New York City, New York, USA.
Peter GordonDivision of Infectious Diseases, Department of Internal Medicine, Columbia University Irving Medical Center, New York City, New York, USA.
Magdalena SobieszczykDivision of Infectious Diseases, Department of Internal Medicine, Columbia University Irving Medical Center, New York City, New York, USA.
Columbia University Irving Medical Center · USNewYork–Presbyterian Hospital · USIcahn School of Medicine at Mount Sinai · USNYU Langone Health · US

Funding

Columbia Partnership for Prevention and Control of HIV/AIDS Clinical Trials UnitUM1AI069470 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAGDALENA ELZBIETA SOBIESZCZYK · 2012 to 2026
$44.8M
Columbia Integrated Training Program in Infectious Diseases ResearchT32AI100852 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI MAGDALENA ELZBIETA SOBIESZCZYK, Anne-Catrin Uhlemann · 2013 to 2026
$2.2M
Harnessing Bioinformatics for HIV Prevention: Understanding Persistence in Comprehensive HIV Prevention ServicesK23AI150378 · NIAID · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI ZUCKER, JASON · 2020 to 2024
$960k
NIAID NIH HHS K23 AI150378NIAID NIH HHS UM1 AI069470
6 · The paper itself

Abstract

HIV pre-exposure prophylaxis (PrEP) effectively reduces new HIV diagnoses. High rates of incident bacterial sexually transmitted infections (STIs) have been observed in patients eligible for and adherent to PrEP. Observational studies generally report low long-term retention in PrEP care. Limited data exist on the rates of bacterial STI diagnosis upon re-engagement with PrEP services. We conducted a retrospective chart review within the HIV prevention program of an urban academic medical center in New York City. Eligible patients started PrEP from 2015 to 2019, then resumed PrEP services after a gap in care of at least 180 days. Demographic, clinical, and laboratory data were used to characterize the patient population and rates of bacterial STI diagnosis at re-engagement. In total, 286 patients were identified, with 316 qualifying re-engagement visits. Twenty-nine percent of patients had continued PrEP during the care gap, and 30% reported discontinuing medication due to a perceived change in risk. A new STI was diagnosed at 19% of re-engagement visits. There was no statistically significant difference in rates of new STI between individuals returning on or off PrEP, nor between those with perceived lower risk and those without. Individuals who fall out of PrEP services and subsequently re-engage remain at high risk of bacterial STI during the gap in care, regardless of whether PrEP medication is continued or the patient perceives themselves to be at lower HIV acquisition risk. Providers should strongly encourage patients discontinuing PrEP to remain engaged in sexual health services. Alternatives to clinic-based PrEP care must still include regular bacterial STI screening.

Indexed as

HIV InfectionsPre-Exposure ProphylaxisSexual and Gender MinoritiesSexually Transmitted DiseasesAmbulatory Care FacilitiesHomosexuality, MaleHumansMaleNew York CityRetrospective Studiesaccess to careHIV preventionPrEPsexually transmitted infections

Identifiers

PMID36383140
PMCPMC9805874
OpenAlexW4309166645

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.